גליבק ® 100 מ"ג ישראל - עברית - Ministry of Health

גליבק ® 100 מ"ג

novartis pharma services ag - imatinib as mesylate 100 mg - film coated tablets - imatinib - glivec is indicated for the treatment of adult patients and children 3 years of age and above with ph+ chronic myeloid leukaemia (ph+ -cml) in chronic phase accelerated phase or blast crisis. glivec is also indicated for the treatment of adult patients with kit (cd117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). glivec is also indicated for the treament of : adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukemia (ph+ all) integrated with chemotherapy. adult patients with relapsed or refractory ph + all as monotherapy. adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. adult patients with myelodyspiastic/myeloproliferative diseases (mds/mpd) associated with pdgfr ( platelet - derived growth factor receptor ) gene re- arrangements. adult patients with hypereosinophilic syndrome (hes) and/or chronic eosinophilic l

גליבק  100 מג ישראל - עברית - Ministry of Health

גליבק 100 מג

novartis israel ltd - imatinib as mesylate - טבליות מצופות פילם - imatinib as mesylate 100 mg - imatinib - imatinib - glivec is indicated for the treatment of adult patients and children 3 years of age and above with ph+ chronic myeloid leukaemia (ph+ -cml) in chronic phase accelerated phase or blast crisis. glivec is also indicated for the treatment of adult patients with kit (cd117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). glivec is also indicated for the treament of : adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukemia (ph+ all) integrated with chemotherapy. adult patients with relapsed or refractory ph + all as monotherapy. adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. adult patients with myelodyspiastic/myeloproliferative diseases (mds/mpd) associated with pdgfr ( platelet - derived growth factor receptor ) gene re- arrangements. adult patients with hypereosinophilic syndrome (hes) and/or chronic eosinophilic l

גליבק   400 מג ישראל - עברית - Ministry of Health

גליבק 400 מג

novartis israel ltd - imatinib as mesylate - טבליות מצופות פילם - imatinib as mesylate 400 mg - imatinib - imatinib - glivec is indicated for the treatment of adult patients and children 3 years of age and above with ph+ chronic myeloid leukaemia (ph+ -cml) in chronic phase accelerated phase or blast crisis. glivec is also indicated for the treatment of adult patients with kit (cd117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). glivec is also indicated for the treament of : adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukemia (ph+ all) integrated with chemotherapy. adult patients with relapsed or refractory ph + all as monotherapy. adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. adult patients with myelodyspiastic/myeloproliferative diseases (mds/mpd) associated with pdgfr ( platelet - derived growth factor receptor ) gene re- arrangements. adult patients with hypereosinophilic syndrome (hes) and/or chronic eosinophilic l

פייקומפה 2 מג טבליות מצופות ישראל - עברית - Ministry of Health

פייקומפה 2 מג טבליות מצופות

eisai israel ltd., israel - perampanel as anhydrous - טבליות מצופות פילם - perampanel as anhydrous 2 mg - perampanel - perampanel - fycompa is indicated for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in patients with epilepsy aged 12 years and older.

פייקומפה 4 מג טבליות מצופות ישראל - עברית - Ministry of Health

פייקומפה 4 מג טבליות מצופות

eisai israel ltd., israel - perampanel as anhydrous - טבליות מצופות פילם - perampanel as anhydrous 4 mg - perampanel - perampanel - fycompa is indicated for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in patients with epilepsy aged 12 years and older.

פייקומפה 6 מג טבליות מצופות ישראל - עברית - Ministry of Health

פייקומפה 6 מג טבליות מצופות

eisai israel ltd., israel - perampanel as anhydrous - טבליות מצופות פילם - perampanel as anhydrous 6 mg - perampanel - perampanel - fycompa is indicated for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in patients with epilepsy aged 12 years and older.

פייקומפה 8 מג טבליות מצופות ישראל - עברית - Ministry of Health

פייקומפה 8 מג טבליות מצופות

eisai israel ltd., israel - perampanel as anhydrous - טבליות מצופות פילם - perampanel as anhydrous 8 mg - perampanel - perampanel - fycompa is indicated for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in patients with epilepsy aged 12 years and older.

פייקומפה 10 מג טבליות מצופות ישראל - עברית - Ministry of Health

פייקומפה 10 מג טבליות מצופות

eisai israel ltd., israel - perampanel as anhydrous - טבליות מצופות פילם - perampanel as anhydrous 10 mg - perampanel - perampanel - fycompa is indicated for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in patients with epilepsy aged 12 years and older.

פייקומפה 12 מג טבליות מצופות ישראל - עברית - Ministry of Health

פייקומפה 12 מג טבליות מצופות

eisai israel ltd., israel - perampanel as anhydrous - טבליות מצופות פילם - perampanel as anhydrous 12 mg - perampanel - perampanel - fycompa is indicated for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in patients with epilepsy aged 12 years and older.

זולאייר   150 מג ישראל - עברית - Ministry of Health

זולאייר 150 מג

novartis israel ltd - omalizumab - אבקה וממס להכנת תמיסה להזרקה - omalizumab 150 mg/dose - omalizumab - omalizumab - xolair is indicated for adults and adolescents (12 years of age and above) with moderate to severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids. xolair has been shown to decrease the incidence of asthma exacerbations in these patients. safety and efficacy have not been established in other allergic conditions.